UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/524,162	06/17/2005	Theodore J Nitz	MICRODOSE 09.06	2828
27667 HAYES SOLO	7590 02/04/201 WAY P.C.		EXAMINER	
3450 E. SUNRI	ISE DRIVE, SUITE 14		KOSACK, JOSEPH R	
TUCSON, AZ 85718			ART UNIT	PAPER NUMBER
			1626	
			NOTIFICATION DATE	DELIVERY MODE
			02/04/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

admin@hayes-soloway.com smckniff@hayes-soloway.com nsoloway@hayes-soloway.com

	Application No.	Applicant(s)	
	10/524,162	NITZ ET AL.	
Office Action Summary	Examiner	Art Unit	
	Joseph R. Kosack	1626	
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet wit	h the correspondence addre	ss
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING ID. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC .136(a). In no event, however, may a red d will apply and will expire SIX (6) MONT te, cause the application to become ABA	ATION. bly be timely filed HS from the mailing date of this commuNDONED (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on <u>05 .</u> 2a) ☐ This action is FINAL . 2b) ☐ This action is application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matte	•	erits is
Disposition of Claims			
4) ☑ Claim(s) 36-66 and 68 is/are pending in the a 4a) Of the above claim(s) is/are withdra 5) ☑ Claim(s) 33-42,56-66 and 68 is/are allowed. 6) ☑ Claim(s) 43-55 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to be drawing(s) be held in abeyand ction is required if the drawing(s	ee. See 37 CFR 1.85(a). s) is objected to. See 37 CFR	, ,
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	nts have been received. nts have been received in Apority documents have been real (PCT Rule 17.2(a)).	oplication No received in this National Sta	age
Attachment(s) 1) Notice of References Cited (PTO-892)		Immary (PTO-413)	
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/22/2010. 	_	/Mail Date formal Patent Application 	

DETAILED ACTION

Claims 36-66 and 68 are pending in the instant application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on December 22, 2010 has been entered.

Information Disclosure Statement

The Information Disclosure Statement filed on December 22, 2010 has been considered by the Examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 43-55 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating a pneumovirus infection, does not reasonably provide enablement for preventing a pneumovirus infection. The specification does not enable any person skilled in the art to which it pertains, or with

Application/Control Number: 10/524,162 Page 3

Art Unit: 1626

which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

The breadth of the claims and the nature of the inventions is to provide a composition of claim 36 in an amount to prevent or treat a pneumovirus infection. The specification shows Examples of compounds of the instant invention to inhibit pneumovirus replication on pages 113-114 in Example 51. The specification also teaches that the compounds of the instant invention are useful in treating and preventing pneumovius infections in humans as well as livestock. The specification does not define expressly what is meant by the term prevention, and so the term must be given its broadest reasonable interpretation. Therefore, as the claims now read, the claims are drawn to a method to prevent an infection from occurring. An infection can occur when just one virus enters the human body, even if the virus does not produce any symptoms. The specification does not show any evidence that this is possible.

The Applicant has submitted a declaration from Dr. Robert O. Cook which demonstrates that one species within the compounds of claim 36 can indeed show prophylactic activity towards pneumovirus, but does not show where there would be no pneumovirus infection possible with a preventative dose of the compound. Therefore, undue experimentation would be required in order to enable the person of skill to practice the invention to the full scope of the claims since no compound has been found that is able to prevent the ability of pneumovirus from entering a human or other animal's body.

Conclusion

Application/Control Number: 10/524,162 Page 4

Art Unit: 1626

Claims 43-55 are rejected. Claims 36-42, 56-66, and 68 are currently allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph R. Kosack whose telephone number is (571)272-5575. The examiner can normally be reached on M-Th 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Joseph R Kosack/ Primary Examiner, Art Unit 1626